Biotech Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Private, Subsidiary
- Established
- 2000-08-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biotechplc.com
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT05278728
- Locations
- 🇨🇳
China People's Liberation Army (PLA)81 Hospital, Nanjing, Jiangsu, China
🇨🇳Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1931
- Registration Number
- NCT04949503
- Locations
- 🇨🇳
First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, Shannxi, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Drug: Nimotuzumab+CRT(concurrent IMRT and TMZ)
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04532229
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳The Third People's Hospital of Zhengzhou, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital of Centre-south University, Changsha, Hunan, China
Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2018-01-03
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT03388372
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
🇨🇳Guangdong Brain Hospital, Guangdong, China
🇨🇳Shenzhen People's Hospital, Shenzhen, China
Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis
- Conditions
- Psoriasis
- Interventions
- Biological: T1h
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 11
- Registration Number
- NCT02649270
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, BeiJing, Beijing, China
Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinomas
- Interventions
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 504
- Registration Number
- NCT02611700
- Locations
- 🇨🇳
Chinese PLA General Hospital Medical School of Chinese PLA, Beijing, Beijing, China
🇨🇳Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳AnHui Provincial Hospital, Hefei, Anhui, China
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02591784
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
🇨🇳The Affiliated tumour hosiptal of HARBIN Medical University, Harbin, Heilongjiang, China
🇨🇳Qilu Hospital,Shandong University, Jinan, Shandong, China
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02549261
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02395068
- Locations
- 🇨🇳
Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT02395016
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China